Added to YB: 2025-05-19
Pitch date: 2025-05-15
MEDP [neutral]
Medpace Holdings, Inc.
+106.13%
current return
Author Info
Compound & Fire shares at least one company deep dive every month. Sign up for the newsletter.
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Market Cap
$16.9B
Pitch Price
$297.35
Price Target
470.20 (-23%)
Dividend
N/A
EV/EBITDA
25.24
P/E
35.52
EV/Sales
5.95
Sector
Life Sciences Tools and Services
Category
growth
Medpace: A High-Science CRO Compounder in a Dynamic Market
MEDP (deep dive): Leading full-service CRO for small/mid biotechs with 23% revenue CAGR 2015-2024. Vertically integrated labs drive strong margins (22.8% EBITDA) and FCF ($572M in 2024). Concerns: declining book-to-bill ratio (0.9x Q1'25) signals growth challenges. Undervalued at current price assuming 8% growth, offering potential 12.2% annual return.
Read full article (20 min)